Coagulation Factor Ix, Human-Lans
Coagulation Factor IX Human-Lans is a plasma-derived blood clotting factor replacement therapy used to treat and prevent bleeding episodes in patients with hemophilia B, a genetic bleeding disorder caused by Factor IX deficiency. This pin-variant (plasma-derived) formulation provides exogenous Factor IX to restore the coagulation cascade's ability to form stable clots. It is administered intravenously and may be used for on-demand treatment of acute bleeding, surgical coverage, or prophylactic regimens to prevent spontaneous bleeding events.
A plasma-derived Factor IX replacement therapy for managing hemophilia B by restoring deficient clotting factor to prevent or treat bleeding.
Key facts at a glance
- RxNorm
- 2643192
- Generic
- Coagulation Factor Ix, Human-Lans
- Class
- pin-variant
- Brands
- Balfaxar
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treatment and prevention of bleeding in patients with congenital hemophilia B (Factor IX deficiency), including on-demand treatment of acute hemorrhagic episodes, surgical bleeding management, and routine prophylaxis to reduce bleeding frequency.
Replaces deficient or absent endogenous Factor IX, a critical component of the intrinsic coagulation pathway. Factor IX complexes with Factor VIII, calcium, and phospholipids to activate Factor X, ultimately leading to thrombin generation and fibrin clot formation.
Derived from human plasma with viral inactivation processes; carries theoretical risk of blood-borne pathogen transmission. Contraindicated in patients with known hypersensitivity to mouse proteins (if applicable) or hamster proteins. Monitoring Factor IX levels is recommended to ensure therapeutic response and avoid excessive levels that may increase thrombotic risk.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy